Name: 4D-150 in Neovascular age-related macular degeneration: Indication
Published: 2026-09-17T18:33:01-04:00

Product information and disease description Product description Product information

Indication

3 evidence topics · 3 sources

Indication under investigation

“4D-150 is being developed for wet AMD and diabetic macular edema (DME), which both affect millions of patients globally, with the goal of freeing patients from burdensome injections while preserving vision.” (opens the source at this quote in a new tab)

Population studied in 4FRONT-1

“Treatment naïve MNV secondary to nAMD in the study eye” (opens the source at this quote in a new tab)
“BCVA between 25 and 78 ETDRS letters, inclusive (20/320-20/32 Snellen equivalent) in the study eye at the Screening Visit” (opens the source at this quote in a new tab)

Population studied in 4FRONT-2

“Previously treated with no more than 4 IVT anti-VEGF injections due to nAMD and received diagnosis of nAMD no more than 6 months prior to the Screening Visit AND documented evidence of anatomical improvement and visual stability/improvement in response to previous IVT anti-VEGF treatment, as determined by the Investigator” (opens the source at this quote in a new tab)

Approved indication and labeled population

Not applicable.